    Pat Cotroneo | FibroGen Inc | ZoomInfo.com 

Pat Cotroneo's involvement in venture capital (via Fibrogen Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/210187-pat-cotroneosection=people&subsection=detail&id=210187




			Search deals by company name, industry, location, investors...			
			




SEARCH


PatCotroneoGet alertedif Pat Cotroneo gets funded!Pat CotroneoFibrogen Inc - Executive Officer, Vice President, Finance, and Chief Financial OfficerDeals involving Pat Cotroneo$120,000,000 raised with Fibrogen Inc on April, 2017$167,700,000 raised with Fibrogen Inc on January, 2015$20,000,000 raised with Fibrogen Inc on December, 2014Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Pat Cotroneo on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!


Pat Carlo Cotroneo - San Bruno, CA | Intelius



























Sign In



We found Pat Carlo Cotroneo in San Bruno, CA


Pat Carlo Cotroneo

                                                                           Intelius found that Pat Carlo Cotroneo  is  a male between 50 and 60 years old from San Bruno, CA.  We have connected them to
                9 addresses,
                4 phones,
                and 9 relatives or associates.
         






Get Report Now

Age

Pat Carlo Cotroneo is in his 50s

Pat Has Lived In

San Bruno, CA
San Francisco, CA
South San Francisco, CA

Pat's Relatives

Eileen Cotroneo
Domenico Cotroneo
Caternia Cotroneo
Annamaria Cotroneo







Pat Carlo Cotroneo



Zodiac SignPisces



GenderMale



Professional Status
Vice President Finance, and Chief at Fibrogen Inc



Get Report Now










Want to know more about Pat? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Pat, or use our people search engine to find others.
Get Background Check on Pat Carlo Cotroneo
Get a Criminal Check on Pat Carlo Cotroneo
Get a Public Record Report on Pat Carlo Cotroneo
Get a People Search Report on Pat Carlo Cotroneo


Pat Carlo Cotroneo's Contact Information
Known Cities Lived In
Find out where Pat Carlo Cotroneo has lived as well as Pat Carlo Cotroneo's phone numbers and email addresses.




Pat Carlo Cotroneo Has Lived in 2 States
California Address for Pat Carlo Cotroneo


141 P******* C* 

San Bruno, CA


Has Lived In

San Bruno, CA
San Francisco, CA


Get Full Address Report










Phone Numbers Associated with Pat Carlo Cotroneo

(415) ***-****
(650) ***-**** - San Bruno, CA 
(415) ***-**** - San Francisco, CA 


Get Full Phone Report



Email Addresses Associated with Pat Carlo Cotroneo

p*******o@***.com
p*******o@***.net
a****c@***.com


Get Email Report




Pat Carlo Cotroneo's Education Information
Known Schools Attended
Learn about Pat Carlo Cotroneo's academic history.  Find out which schools Pat Carlo Cotroneo attended, the dates attended as well as the degrees Pat Carlo Cotroneo received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Pat Carlo Cotroneo Has Attended 2 Schools
University of San Francisco Pat Carlo Cotroneo has a Acccounting in Acccounting               
Sierra High School               1978 – 1982                              


Pat Carlo Cotroneo's Professional Information
Information regarding Pat Carlo Cotroneo's professional history.  Find out previous places Pat Carlo Cotroneo has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Pat Carlo Cotroneo Has Worked at 3 Places
Company: Fibrogen Inc
               Title: Vice President Finance, and Chief
Company: Fibrogen Inc
               Title: Chief Financial Officer
Pat Carlo Cotroneo's Experience
Title: Vice President Finance, and Chief
               Company: Fibrogen Inc
Job Details
               Company Size: $100 mil to less than $250 mil - Employee Range: 100 to less than 500
Title: Chief Financial Officer
               Company: Fibrogen Inc
Job Details
               Company Size: $25 mil to less than $50 mil - Employee Range: 100 to less than 500. Company Size: $100 mil to less than $250 mil - Employee Range: 100 to less than 500.
Additional Professional Information on Pat Carlo Cotroneo

 See Pat Carlo Cotroneo's LinkedIn Profile



Pat Carlo Cotroneo's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Pat Carlo Cotroneo


Pat Carlo Cotroneo's known Social Networks And Potential Email Matches

Find all of Pat Carlo Cotroneo's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Pat Cotroneo
Username Matches

                  PatCotroneo
                  CotroneoPat
                  Pat.Cotroneo
                  Cotroneo.Pat
                  Pat_Cotroneo
                  Cotroneo_Pat
                  Pat-Cotroneo
                  Cotroneo-Pat
                  PCotroneo
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
P Cotroneo







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.













Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version














Pat Cotroneo: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 6:27 AM ET
Biotechnology

Company Overview of FibroGen, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Pat   Cotroneo  Chief Financial Officer and Vice President of Finance, FibroGen, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 1 different industries.53$2,061,295As of Fiscal Year 2016
Background

		Mr. Pat Cotroneo has been Chief Financial Officer of FibroGen, Inc since 2008 and serves as its Vice President of Finance. Mr. Cotroneo joined us in 2000 as Controller. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. He was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a B.S. with honors ... from the University of San Francisco.Read Full Background




Corporate Headquarters
409 Illinois StreetSan Francisco, California 94158United StatesPhone: 415-978-1200Fax: 415-978-1902
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
BS University of San Francisco
Other Affiliations
University of San Francisco


Annual Compensation
Salary$440,000Total Annual Compensation$440,000
Stocks Options
Restricted Stock Awards$684,351All Other Compensation$16,976Exercised Options$9,270Exercised Options Value$141,640Exercisable Options$386,068Exercisable Options Value$4,751,489Unexercisable Options$121,625Unexercisable Options Value$244,056Total Value of Options$5,137,184Total Number of Options$516,963
Total Compensation
Total Annual Cash Compensation$690,748Total Short Term Compensation$440,000Other Long Term Compensation$701,327Total Calculated Compensation$2,061,295




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationDavid A. Ricks Chairman, Chief Executive Officer & PresidentEli Lilly and Company--Compensation as of Fiscal Year --.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact FibroGen, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft













Pat Cotroneo of FibroGen Inc Executive Profile

















 












Welcome!















Company News
Company Site
Premium
Log In


 



















Membership
Home
Portfolio
Stocks
Bonds
Funds
ETFs
CEF
Markets
Tools
Real Life Finance
Discuss





Investing Ideas


Fund Analyst Picks
Picks by Category
Fund Pick Performance
Picks & Pans E-Newsletter
Fund Spy Column
Fund Spy Book
Bond Squad
Fund Video Reports
FundInvestor Newsletter
ETF Investing
Fund Family Experts



Fund Reports


All Fund Analyst Reports
Fund Stewardship Reports



Fund Ratings


Highest-Rated Value
Highest-Rated Growth
Highest-Rated Large-Cap
Highest-Rated Mid-Cap
Highest-Rated Small-Cap
Foreign Fund Standouts
Star Rating Performance
Rating Methodology



Fund Performance


Top 1-Month Performers
Top YTD Performers
Top 1-Year Performers
Top 3-Year Performers
Top 5-Year Performers
Fund Category Returns
Biggest Daily NAV Changes
Closed-End Funds
Exchange-Traded Funds
Quarterly Market Outlook



Fund Screeners


Basic Screeners
Fund Screener
Long-Term Winners
Solid Small-Growth Funds
Conservative Bond Funds

Premium Screeners
Premium Fund Screener
Index Funds
Hidden Gems
Lower-Risk Foreign Funds


Video Center
 
 

 



 



FibroGen Inc
 FGEN


Add to PortfolioGet E-mail AlertsPrint This PagePDF ReportData QuestionQuoteChartStock AnalysisPerformanceKey RatiosFinancialsValuationInsidersOwnershipFilingsBondsOverviewExecutive CompensationInsider ActivityKey ExecutivesBoard of DirectorsCommittees
 


Key Executives
                > Pat Cotroneo
            
Pat Cotroneo, Vice President, Finance and Chief Financial Officer



Profile
Connections






Biography



    Pat Cotroneo has served as our Chief Financial Officer since 2008. Mr. Cotroneo joined us in 2000 as Controller, was promoted to Vice President of Finance, and subsequently promoted to Chief Financial Officer in 2008. Prior to joining us, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and Genetic Therapy, Inc. (Novartis subsidiaries) from 1993 to 2000. Prior to SyStemix, he was employed by Deloitte & Touche from 1987 to 1993 in various positions. Mr. Cotroneo received a B.S. with honors from the University of San Francisco and was selected a Louise M. Davies scholar.
    





Board Membership




Pat Cotroneo is not a member of any boards




 


  







We value your feedback. Let us know what you think.













 


Site Directory
Site Map
Our Products












 



 



 




Corrections
Help
Advertising Opportunities
Licensing Opportunities
Glossary
RSS
Mobile Portfolio
Affiliate
Careers 
 


International Sites:
        	Australia
Canada
China
France
Germany
Hong Kong
Italy
The Netherlands
Norway
Spain
U.K.
Switzerland

 




Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry



Premium Stocks by:
            Name
|
Ticker
|
Star Rating
|
Market Cap
|
Stock Type
|
Sector
|
Industry



Premium Mutual Funds by:
            Star Rating
|
Investment Style
|
Total Assets
|
Category
|
Top Holdings
|
Top Sectors
|
Symbol / Ticker
|
Name



Premium ETFs by:
            Star Rating
|
Category
|
Total Assets
|
Symbol / Ticker
|
Name



Popular Articles by:
            Title
|
Date
|
Author
|
Collection
|
Interest
|
Popularity



Popular Investment Categories by:
            Topic
|
Sector
|
Key Indicators
|
User Interest
|
Market Cap
|
Industry




Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.
        © Copyright  Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. Russell 2000 quote is 10 minutes delayed.
 


 























Executive Team | FibroGen | BioPharma for Anemia, Fibrosis, Cancer























































FibroGen China
Newsroom
Contact
 














MENU
MENU













Executive Team








Our leadership is deeply committed to developing first-in-class medicines and bringing together a dedicated team of experts to achieve this goal.










 
Thomas B. Neff
Chairman, Founder, and Chief Executive Officer 






close x

 

close x

Thomas B. Neff
Chairman, Founder, and Chief Executive Officer Mr. Neff founded FibroGen, Inc., in 1993, and has served since that time as Chairman and Chief Executive Officer and as a member of our Board of Directors. Prior to founding FibroGen, Mr. Neff was a founder and managing general partner of two investment partnerships that pioneered the use of royalty interests to fund clinical development and ultimately led to the formation of Royalty Pharma, a global leader in the acquisition of royalty interests. Earlier in his career, Mr. Neff was Senior Vice President at Lazard Frères & Co. and an investment banker at PaineWebber Group (now UBS). Mr. Neff is a member of the Board of Trustees at Claremont McKenna College, and serves as a Director of FibroGen China Anemia Holdings, Ltd., and General Manager of FibroGen (China) Medical Technology Development Co., Ltd. He was a fellow of the Thomas Watson Foundation, and completed his undergraduate studies at Claremont McKenna College, with concentrations in molecular biology and government, and pursued graduate studies at the University of Chicago in economics and finance. Mr. Neff received a Doctor of Medicine degree, honoris causa, from Oulu University, Oulu, Finland in 2009.





‹
K. Peony Yu, M.D.Previous


Karen L. BergmanNext
›














 
Karen L. Bergman
Vice President, Investor Relations and Corporate Communications 






close x

 

close x

Karen L. Bergman
Vice President, Investor Relations and Corporate Communications Ms. Bergman joined FibroGen as Vice President, Investor Relations and Corporate Communications, in 2016. She brings more than 25 years of experience in the pharmaceutical, biotechnology, and medical technology sectors. She has held leadership roles in investor relations, corporate, product, employee and financial communications, and corporate marketing at a number of companies and consultancies. Ms. Bergman, most recently, was the president and co-founder of BCC Partners, LLC, a life sciences and healthcare investor relations and communications strategic advisory firm. Prior, she was Vice President of Corporate Communications and Investor Relations at ALZA Corporation (now Johnson & Johnson), where she supported the company’s transition and success from an R&D company developing products for leading pharmaceutical companies to a commercial organization with marketed products in multiple specialty franchise areas in oncology, urology, endocrinology, neurology and hospital settings. Prior to ALZA, she led the life sciences practice at Burns McClellan Inc. in New York. Ms. Bergman earned her B.A. at Yale University, where she graduated  cum laude  with distinction.





‹
Thomas B. NeffPrevious


Christine L. ChungNext
›














 
Christine L. Chung
Vice President, China Operations 






close x

 

close x

Christine L. Chung
Vice President, China Operations Ms. Chung is Vice President, China Operations, and Managing Director of our subsidiary company, FibroGen China. She joined the company in 2007 and brings more than 25 years of experience in growing businesses from start-up through various phases of corporate development. Ms. Chung serves in the role of Project Leader of our U.S.-based China development efforts and has overall responsibility for our China local operations. Under Ms. Chung’s leadership, our China strategy has advanced from conceptualization to pre-launch. Prior to joining FibroGen, Ms. Chung was Vice President, Business Development, at eMed Technologies and a management consultant with Monitor Group, the predecessor company of Monitor Deloitte. Ms. Chung received her B.A., magna cum laude, from Harvard University and is a native of Hong Kong.





‹
Karen L. BergmanPrevious


Pat CotroneoNext
›














 
Pat Cotroneo
Vice President, Finance, and Chief Financial Officer 






close x

 

close x

Pat Cotroneo
Vice President, Finance, and Chief Financial Officer Mr. Cotroneo is our Chief Financial Officer, with responsibility for finance and accounting operations, Human Resources, and Information Technology. Mr. Cotroneo joined FibroGen in 2000 and has served as our CFO since 2008. Mr. Cotroneo brings 25 years experience in senior financial management in the life sciences sector. Prior to joining FibroGen, Mr. Cotroneo was at SyStemix, Inc. where he assumed Controller responsibilities for both SyStemix and for Genetic Therapy, Inc. (now Novartis) from 1993 to 2000. Prior to Novartis, Mr. Cotroneo was employed for seven years by Deloitte. Mr. Cotroneo received a B.S. degree with honors from the University of San Francisco and was selected as a Louise M. Davies Scholar.





‹
Christine L. ChungPrevious


Richard FarleyNext
›














 
Richard Farley
Vice President, Human Resources 






close x

 

close x

Richard Farley
Vice President, Human Resources Mr. Farley is Vice President, Human Resources, and joined FibroGen in 2015. Mr. Farley has more than 30 years of human resources experience at several leading companies. Prior to joining FibroGen, Mr. Farley served as Vice President, Human Resources, at XenoPort, Inc. Previously, Mr. Farley worked at Amgen, where he oversaw HR activities for numerous Research and Development groups in Thousand Oaks, Seattle, and Burnaby, Canada. Mr. Farley has also held human resource and administrative leadership roles at ViroPharma (now Shire Plc), Sphinx Pharmaceuticals (now Eli Lilly), Eli Lilly and Company, and Hewlett Packard. Mr. Farley holds a B.S. degree in Industrial and Labor Relations from Syracuse University and an M.B.A. from Duke University.





‹
Pat CotroneoPrevious


R. Wayne Frost, Pharm.D., J.D.Next
›














 
R. Wayne Frost, Pharm.D., J.D.
Vice President, Regulatory Affairs 






close x

 

close x

R. Wayne Frost, Pharm.D., J.D.
Vice President, Regulatory Affairs Dr. Frost is Vice President, Regulatory Affairs, and joined FibroGen in 2010, bringing more than 20 years of pharmaceutical industry experience in regulatory affairs and drug development. Prior to joining FibroGen, he served as Vice President of Regulatory Affairs and Quality Assurance at Sangart Metabasis Therapeutics Inc. (now Ligand Pharmaceuticals), and Prometheus Laboratories Inc. Previously, Dr. Frost served as: Global Regulatory Leader for ARANESP® at Amgen; Regulatory Therapeutic Area Head for Respiratory, Allergy, Inflammation, Immunology and Oncology at Pfizer Global Research and Development; and Head of Regulatory for Local Anesthetics and Critical Care Therapeutics at Astra Pharmaceuticals (now AstraZeneca). He also worked at Bayer Pharmaceuticals in antibiotic drug development and at Key Pharmaceuticals in drug delivery. Dr. Frost is a guest lecturer on Food and Drug Law at Yale University School of Medicine, Department of Pharmacoepidemiology and Public Health. He completed a Pharm.D. from Creighton University School of Pharmacy and a post-doctoral fellowship in pharmacokinetics/infectious diseases at SUNY-Buffalo. He received a J.D. from the University of Connecticut School of Law.





‹
Richard FarleyPrevious


M. Sean Healy, Ph.D.Next
›














 
M. Sean Healy, Ph.D.
Vice President, Quality 






close x

 

close x

M. Sean Healy, Ph.D.
Vice President, Quality Dr. Healy is Vice President, Quality, and joined the company in 2016. Dr. Healy has more than 22 years of industry experience, with 16 years of experience in management of quality systems and quality assurance for biotechnology companies across all stages of drug development. Most recently, he served as Vice President of Quality at Cellerant Therapeutics, where he established both the quality assurance (QA) and quality control (QC) departments, including building an in-house QC laboratory. Prior to Cellerant, Dr. Healy led QA Operations and QC for commercial product programs at Ipsen and led good manufacturing practice (GMP) QA at Theravance, where he had significant responsibility for commercial preparations and launch of Vibativ®. Dr. Healy also provided QA oversight for several late-stage clinical and commercial products at Pfizer. Dr. Healy obtained his Ph.D. in Physical/Analytical Chemistry from Seton Hall University.





‹
R. Wayne Frost, Pharm.D., J.D.Previous


Elias Kouchakji, M.D.Next
›














 
Elias Kouchakji, M.D.
Vice President, Clinical Development, Drug Safety, and Pharmacovigilance 






close x

 

close x

Elias Kouchakji, M.D.
Vice President, Clinical Development, Drug Safety, and Pharmacovigilance Dr. Kouchakji, Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, joined FibroGen in 2014, bringing more than 25 years of experience in product development, drug safety, and clinical practice. Previously, he served as Executive Medical Director, Safety, at Amgen, Inc., supporting the development and commercialization of Aranesp®, among other programs. Prior, Dr. Kouchakji was the Global Head Pharmacovigilance and Risk Management at Elan Pharmaceuticals, Inc. (now Perrigo Company plc), Head of U.S. Safety at Hoffmann-La Roche (Roche), and Director, Drug Safety and Pharmacovigilance at Serono (now EMD Serono). Prior to his transition to industry, Dr. Kouchakji was a practicing physician with specialization in surgery, having earned his M.D. at Damascus University.





‹
M. Sean Healy, Ph.D.Previous


Al Y. Lin, M.D., Ph.D.Next
›














 
Al Y. Lin, M.D., Ph.D.
Vice President, Drug Development 






close x

 

close x

Al Y. Lin, M.D., Ph.D.
Vice President, Drug Development Dr. Lin is our Vice President, Drug Development, and oversees preclinical research and development (R&D) and Chemistry, Manufacturing, and Controls (CMC) development, and quality and supply chain management functions. Dr. Lin joined FibroGen in 1999, and has more than 30 years of drug discovery, development, and clinical experience. Prior to joining FibroGen, he was Head of In Vivo Pharmacology at Bayer and served as a Senoir Scientist at XOMA Corporation. He received his Ph.D. from St. Louis University and post-doctoral training at the University of Virginia. He completed his clinical residency training at and received his medical degree from Nanjing Medical University, China. Dr. Lin is a native of Nanjing, China. 





‹
Elias Kouchakji, M.D.Previous


Michael D. Lowenstein, J.D.Next
›














 
Michael D. Lowenstein, J.D.
Chief Legal Counsel 






close x

 

close x

Michael D. Lowenstein, J.D.
Chief Legal Counsel Mr. Lowenstein, Chief Legal Counsel, joined the company in 2003. Mr. Lowenstein has nearly 20 years of legal practice with a particular emphasis on corporate and securities law and life science transactions. Prior to joining FibroGen, Mr. Lowenstein practiced at Wilson Sonsini Goodrich & Rosati, where he focused on corporate law, securities, mergers and acquisitions (M&A), and strategic transactions. He earned a J.D. from Columbia University, where he was a Harlan Fiske Stone Scholar, and a B.A., magna cum laude, from Brown University. Mr. Lowenstein is a member of the State Bar of California.





‹
Al Y. Lin, M.D., Ph.D.Previous


Michael J. Martinelli, Ph.D.Next
›














 
Michael J. Martinelli, Ph.D.
Vice President, Technical Development 






close x

 

close x

Michael J. Martinelli, Ph.D.
Vice President, Technical Development Dr. Martinelli joined FibroGen as Vice President, Technical Development, in 2011. Dr. Martinelli has more than 30 years of experience in chemical research and development, automation technologies, and pharmaceutical research and development. He led the Chemistry, Manufacturing, and Controls (CMC) development of numerous investigational new drug (IND) programs, leading to many successful new drug applications (NDAs) and product launches. Most recently, he served as Vice President, Pharmaceutical Development for Arena Pharmaceuticals in San Diego. Prior to joining Arena, he was Executive Director of Research, Chemical Process & Technologies, at Amgen Inc. Earlier in his career; Dr. Martinelli held numerous roles at Eli Lilly and Company, overseeing Chemical Process Research and Development. He held post-doctoral fellowships at the University of Munich and Harvard University, and was elected as a Fellow to the Royal Society of Chemistry. Dr. Martinelli has organized many international scientific conferences, and is a reviewer for more than 10 scientific journals and an editor for scientific monographs. Dr. Martinelli received his B.S. in Chemistry from the State University of New York at Geneseo and a Ph.D. in Organic Chemistry from Wesleyan University.





‹
Michael D. Lowenstein, J.D.Previous


James W. Polarek, Ph.D.Next
›














 
James W. Polarek, Ph.D.
Vice President, Protein Therapeutics and Collagen Development 






close x

 

close x

James W. Polarek, Ph.D.
Vice President, Protein Therapeutics and Collagen Development Dr. Polarek, Vice President of Protein Therapeutics and Collagen Development, and board member of FibroGen Europe Ltd., joined FibroGen in 1995. Previously, Dr. Polarek served as Senior Director of both Tissue Bioengineering Research and Process Development at Telios Pharmaceuticals Inc. (now Integra LifeSciences), where he developed tissue engineering therapeutics, designed and implemented a multi-department team to develop manufacturing processes, and managed multidisciplinary teams throughout product development. Dr. Polarek received his B.S. in Biochemistry from UCLA and his Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.





‹
Michael J. Martinelli, Ph.D.Previous


Seth Porter, Ph.D.Next
›














 
Seth Porter, Ph.D.
Vice President, Fibrosis Therapeutics 






close x

 

close x

Seth Porter, Ph.D.
Vice President, Fibrosis Therapeutics Dr. Porter, Vice President, Fibrosis Therapeutics, joined FibroGen in 2005, and has been leading the pamrevlumab development program since 2007. He brings more than 25 years of clinical and preclinical experience in research, drug development, bioanalytics, and project development across multiple therapeutic areas. Prior to joining FibroGen, Dr. Porter held several research and development positions in pharmaceutical and biotechnology companies in the San Francisco Bay Area, including Adamas Pharmaceuticals, Cerus Corporation, Genentech, Syntex Laboratories (now Roche) and Athena Neurosciences (acquired by Elan Pharmaceuticals plc). He received a Ph.D. in Biochemistry from Dartmouth Medical School in 1984 and completed his post-doctoral training in Biochemistry and Neurobiology at Washington University Medical School.





‹
James W. Polarek, Ph.D.Previous


Leanne C. Price, J.D.Next
›














 
Leanne C. Price, J.D.
Chief Intellectual Property Counsel 






close x

 

close x

Leanne C. Price, J.D.
Chief Intellectual Property Counsel Ms. Price, Chief Intellectual Property Counsel, joined FibroGen in 1999. She has approximately 25 years of in-house and law firm experience with an emphasis on patent portfolio development and defense and intellectual property strategy in the biotechnology and pharmaceutical industries. Ms. Price was previously Senior Patent Attorney at Incyte Pharmaceuticals, where she was responsible for global management of Incyte’s core technology portfolio. Prior, Ms. Price was an associate at the Silicon Valley law firm of Skjerven Morrill MacPherson Franklin & Friel LLP, focused on the areas of patent prosecution and defense, licensing, and intellectual property counseling. Ms. Price received a B.S. in Molecular Biology and a B.A. in History Honors with high distinction from Revelle College at the University of California, San Diego. She received her J.D. from Boalt Hall, School of Law (University of California, Berkeley). Ms. Price is a member of the State Bar of California and is registered to practice before the United States Patent and Trademark Office.





‹
Seth Porter, Ph.D.Previous


K. Peony Yu, M.D.Next
›














 
K. Peony Yu, M.D.
Chief Medical Officer 






close x

 

close x

K. Peony Yu, M.D.
Chief Medical Officer Dr. Yu, Chief Medical Officer, joined FibroGen in 2008. Dr. Yu oversees all global and regional clinical development strategies and execution of the various clinical programs, as well as providing leadership for the roxadustat program. She brings more than 25 years of pharmaceutical leadership, patient care, and drug development experience with deep expertise in all aspects of clinical and regulatory process, and with multiple prior successful NDA/MAAs  for novel drugs and drug/device combos. Prior to joining FibroGen, Dr. Yu served as Vice President of Clinical Research at Anesiva Inc. Previously, Dr. Yu was Director of Clinical Development at ALZA Corporation (now Johnson & Johnson); Director of Clinical Development at Pain Therapeutics Inc.; and Assistant Director, Clinical Development, at Elan Corporation plc (now Perrigo Company plc). Earlier in her career, Dr. Yu was Head of the Department of Physical Medicine & Rehabilitation at the Palo Alto Medical Foundation. Dr. Yu received a B.S. in Chemical Engineering from University of California, Davis, and an M.D. from the UC Davis School of Medicine. She completed her residency training at Stanford University School of Medicine. Dr. Yu is a native of China.





‹
Leanne C. Price, J.D.Previous


Thomas B. NeffNext
›














 Our Partners 


We are interested in building strong partnerships that complement our strengths.



Learn More



 




 








Pat Cotroneo Profiles | Facebook

FacebookEmail or PhonePasswordForgot account?English (US)EspañolFrançais (France)中文(简体)العربيةPortuguês (Brasil)Italiano한국어Deutschहिन्दी日本語MessengerFacebook LitePeoplePlacesGamesLocationsCelebritiesMarketplaceGroupsRecipesMomentsInstagramAboutCreate AdCreate PageDevelopersCareersPrivacyCookiesAd ChoicesTermsSettingsActivity Log Facebook © 2017



















﻿






























FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - Chaffey Breeze













































 
















 



  
 
 
























Daily Ratings & News for FibroGen Inc

        
	Complete the form below to receive the latest headlines and analysts' recommendationsfor FibroGen Inc with our free daily email newsletter:










Follow @chaffeybreeze












Recent Posts

BofI Holding, Inc. (BOFI) Receives Average Rating of “Buy” from Brokerages
Northeast Investment Management Sells 624 Shares of Alphabet Inc. (NASDAQ:GOOG)
Brokerages Set Rolls-Royce Holding PLC (RR) Target Price at $701.36
Vident Investment Advisory LLC Has $329,000 Position in General Dynamics Corporation (GD)
Oracle Corporation (ORCL) Position Lowered by Usca Ria LLC
Exencial Wealth Advisors LLC Sells 6,025 Shares of Wells Fargo & Company (NYSE:WFC)
LSV Asset Management Has $330.86 Million Stake in Wal-Mart Stores, Inc. (WMT)
Comcast Corporation (CMCSA) Shares Bought by Copeland Capital Management LLC
Blue Fin Capital Inc. Invests $210,000 in 3M Company (MMM)
Hodges Capital Management Inc. Sells 4,592 Shares of American Express Company (AXP)
Sawtooth Solutions LLC Sells 130 Shares of Automatic Data Processing (ADP)
Valero Energy Corporation (VLO) Stake Increased by Teachers Advisors LLC
Lakeview Capital Partners LLC Acquires New Stake in Novartis AG (NVS)
McKesson Corporation (MCK) Stake Held by Bellevue Group AG
Kinder Morgan, Inc. (KMI) Shares Bought by Cypress Asset Management Inc. TX
Fiduciary Group LLC Reduces Stake in BP p.l.c. (BP)
Firsthand Technology Value Fund (NASDAQ:SVVC) Earns Daily News Sentiment Score of 0.27
Sasol (NYSE:SSL) Earning Somewhat Positive Media Coverage, Accern Reports
Susquehanna Bancshares (SUSQ) Receiving Favorable News Coverage, Report Finds
Tantech Holdings (NASDAQ:TANH) Earning Somewhat Favorable Media Coverage, Study Finds







FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares


					Posted by Lucas Kauffman on Jul 18th, 2017 // No Comments




FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $33.45, for a total value of $66,900.00. Following the completion of the sale, the director now directly owns 32,000 shares in the company, valued at $1,070,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 
Kalevi Kurkijarvi also recently made the following trade(s): 


 Get FibroGen Inc alerts:




On Thursday, June 15th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $28.50, for a total value of $57,000.00. 
On Tuesday, May 16th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $27.40, for a total value of $54,800.00. 

Shares of FibroGen, Inc (NASDAQ:FGEN) traded down 1.00% during trading on Tuesday, hitting $34.65. The stock had a trading volume of 264,436 shares. The stock’s 50 day moving average is $28.77 and its 200-day moving average is $25.52. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $35.65. The company’s market cap is $2.42 billion. 





FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.11. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. The business had revenue of $26.89 million for the quarter, compared to analysts’ expectations of $26.02 million.  Analysts forecast that  FibroGen, Inc will post ($1.85) earnings per share for the current year. 
COPYRIGHT VIOLATION WARNING: “FibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares” was originally  reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/18/fibrogen-inc-nasdaqfgen-director-kalevi-kurkijarvi-sells-2000-shares.html. 
Several large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in  FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock valued at $109,811,000 after buying an additional 4,439,882 shares during the period.  FMR LLC boosted its stake in  FibroGen by 72.5% in the fourth quarter. FMR LLC now owns 1,533,431 shares of the biopharmaceutical company’s stock valued at $32,815,000 after buying an additional 644,528 shares during the period.  Norges Bank acquired a new stake in  FibroGen during the fourth quarter valued at about $8,480,000.  Vanguard Group Inc. boosted its stake in  FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock valued at $124,409,000 after buying an additional 392,778 shares during the period.  Finally, Bogle Investment Management L P DE boosted its stake in  FibroGen by 215.8% in the first quarter. Bogle Investment Management L P DE now owns 329,371 shares of the biopharmaceutical company’s stock valued at $8,118,000 after buying an additional 225,083 shares during the period. Institutional investors and hedge funds own  43.83% of the company’s stock. 
FGEN has been the topic of a number of recent research reports. Zacks Investment Research lowered FibroGen from a “hold” rating to a “sell” rating in a research note on Monday, May 8th. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. William Blair  reissued an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Citigroup Inc  reissued a “buy” rating and set a $48.00 price objective on shares of FibroGen in a research note on Monday, June 26th. Finally, Stifel Nicolaus  reissued a “buy” rating and set a $38.00 price objective (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. One analyst  has rated the stock with a sell rating, seven have issued  a buy rating and one  has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $42.17.
About FibroGen
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.







Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.








 






















Latest News





Leave a Reply

Click here to cancel reply.




Name  (Required) 



Mail (will not be published)  (Required) 



Website












 

 











































